Michael L Jackson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3515834/publications.pdf

Version: 2024-02-01

89 papers 5,908 citations

94269 37 h-index 79541 **73** g-index

95 all docs 95
docs citations

95 times ranked 6190 citing authors

#	Article	IF	CITATIONS
1	Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 – King County, Washington. Vaccine, 2022, 40, 122-132.	1.7	19
2	Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems. Vaccine, 2022, 40, 752-756.	1.7	23
3	Vaccine effectiveness against COVIDâ€19 among symptomatic persons aged ≥12 years with reported contact with COVIDâ€19 cases, February–September 2021. Influenza and Other Respiratory Viruses, 2022, 16, 673-679.	1.5	4
4	Epidemiology of Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children One Year of Age and Olderâ€"Washington State, 2011/2012â€"2015/2016. Journal of Infectious Diseases, 2021, 223, 147-156.	1.9	10
5	Characteristics of COVID-19 in Homeless Shelters. Annals of Internal Medicine, 2021, 174, 42-49.	2.0	62
6	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, The, 2021, 397, 398-408.	6.3	144
7	Incidence of Medically Attended Acute Respiratory Illnesses Due to Respiratory Viruses Across the Life Course During the 2018/19 Influenza Season. Clinical Infectious Diseases, 2021, 73, 802-807.	2.9	8
8	Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health, 2021, 21, 516.	1.2	2
9	Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011–2012 through 2018–2019. Vaccine, 2021, 39, 1788-1796.	1.7	13
10	Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study. BMC Infectious Diseases, 2021, 21, 335.	1.3	14
11	Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine, 2021, 39, 3324-3328.	1.7	2
12	Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in $10\ \text{countries}$. ELife, $2021,10,10$	2.8	54
13	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	2.8	50
14	Temporal Trends in Undervaccination: A Population-Based Cohort Study. American Journal of Preventive Medicine, 2021, 61, 64-72.	1.6	9
15	Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February–May 2021. Journal of Infectious Diseases, 2021, , .	1.9	3
16	Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season. Journal of Infectious Diseases, 2020, 221, 8-15.	1.9	150
17	Low-impact social distancing interventions to mitigate local epidemics of SARS-CoV-2. Microbes and Infection, 2020, 22, 611-616.	1.0	11
18	The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology. BMJ Open, 2020, 10, e037295.	0.8	25

#	Article	IF	CITATIONS
19	Postlicensure Evaluation of COVID-19 Vaccines. JAMA - Journal of the American Medical Association, 2020, 324, 1939.	3.8	53
20	Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine, 2020, 38, 5880-5884.	1.7	11
21	Order of Live and Inactivated Vaccines and Risk of Non–vaccine-targeted Infections in US Children 11–23 Months of Age. Pediatric Infectious Disease Journal, 2020, 39, 247-253.	1.1	3
22	Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011â€2016. Influenza and Other Respiratory Viruses, 2020, 14, 380-390.	1.5	5
23	Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clinical Infectious Diseases, 2020, 71, e726-e734.	2.9	7
24	Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ, The, 2020, 369, m1923.	3.0	166
25	Decreasing median age of COVID-19 cases in the United Statesâ€"Changing epidemiology or changing surveillance?. PLoS ONE, 2020, 15, e0240783.	1.1	17
26	Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. Vaccine, 2019, 37, 4392-4400.	1.7	28
27	Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019. Morbidity and Mortality Weekly Report, 2019, 68, 135-139.	9.0	75
28	Incidence of Herpes Zoster Among Children: 2003–2014. Pediatrics, 2019, 144, .	1.0	60
29	Use of self-reported vaccination status can bias vaccine effectiveness estimates from test-negative studies. Vaccine: X, 2019, 1, 100003.	0.9	10
30	Reply to Skowronski, De Serres, and Orenstein. Clinical Infectious Diseases, 2019, 69, 1085-1086.	2.9	2
31	Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853.	2.9	218
32	Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806.	2.9	90
33	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011–2017. Clinical Infectious Diseases, 2019, 68, 1616-1622.	2.9	9
34	Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016. Clinical Infectious Diseases, 2019, 68, 1444-1453.	2.9	126
35	Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. JMIR Research Protocols, 2019, 8, e11333.	0.5	10
36	Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Nonâ€"Vaccine-Targeted Infections From 24 Through 47 Months of Age. JAMA - Journal of the American Medical Association, 2018, 319, 906.	3.8	43

#	Article	IF	CITATIONS
37	Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine, 2018, 36, 1272-1278.	1.7	52
38	The impact of selection bias on vaccine effectiveness estimates from test-negative studies. Vaccine, 2018, 36, 751-757.	1.7	32
39	Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. Academic Pediatrics, 2018, 18, 754-762.	1.0	11
40	Estimated rates of influenzaâ€associated outpatient visits during 2001â€2010 in 6 <scp>US</scp> integrated healthcare delivery organizations. Influenza and Other Respiratory Viruses, 2018, 12, 122-131.	1.5	9
41	Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. Vaccine, 2018, 36, 467-472.	1.7	25
42	Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. PLoS ONE, 2018, 13, e0206117.	1.1	6
43	Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012–2016. Vaccine, 2018, 36, 8047-8053.	1.7	16
44	Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Journal of Infectious Diseases, 2018, 218, 189-196.	1.9	43
45	The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. Health Affairs, 2018, 37, 316-324.	2.5	57
46	Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Pharmacoepidemiology and Drug Safety, 2018, 27, 921-925.	0.9	7
47	Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018. Morbidity and Mortality Weekly Report, 2018, 67, 180-185.	9.0	146
48	Reply to: Quality Indicators of Drug Use and Risk of Pneumonia in Older Adults without Dementia. Journal of the American Geriatrics Society, 2017, 65, 1365-1366.	1.3	0
49	First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. Journal of Pediatrics, 2017, 187, 234-239.e4.	0.9	42
50	Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. Vaccine, 2017, 35, 1873-1878.	1.7	15
51	Patterns of childhood immunization and all-cause mortality. Vaccine, 2017, 35, 6643-6648.	1.7	2
52	Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. New England Journal of Medicine, 2017, 377, 534-543.	13.9	240
53	Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017. Morbidity and Mortality Weekly Report, 2017, 66, 167-171.	9.0	90
54	RE: "INVITED COMMENTARY: BEWARE THE TEST-NEGATIVE DESIGN― American Journal of Epidemiology, 2017, 185, 613-613.	1.6	8

#	Article	IF	CITATIONS
55	Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012–2013. Clinical Infectious Diseases, 2016, 62, civ952.	2.9	30
56	Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011–2012 and 2012–2013. Pediatric Infectious Disease Journal, 2016, 35, 299-308.	1.1	34
57	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. Journal of Infectious Diseases, 2016, 214, 1010-1019.	1.9	101
58	2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clinical Infectious Diseases, 2016, 63, 1564-1573.	2.9	229
59	Predicting 2‥ear Risk of Developing Pneumonia in Older Adults without Dementia. Journal of the American Geriatrics Society, 2016, 64, 1439-1447.	1.3	10
60	Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infectious Diseases, 2016, 16, 503.	1.3	57
61	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics, 2016, 137, e20153279.	1.0	80
62	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States. Journal of Infectious Diseases, 2016, 213, 1546-1556.	1.9	159
63	White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine, 2016, 34, A1-A29.	1.7	35
64	Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstetrics and Gynecology, 2015, 126, 1069-1074.	1.2	86
65	Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine, 2015, 33, 1313-1316.	1.7	65
66	Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type. Journal of Infectious Diseases, 2015, 211, 1529-1540.	1.9	245
67	Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children. Vaccine, 2015, 33, 6736-6744.	1.7	21
68	Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA - Journal of the American Medical Association, 2015, 314, 1581.	3.8	91
69	Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine, 2015, 33, 5181-5187.	1.7	14
70	Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. Morbidity and Mortality Weekly Report, 2015, 64, 10-5.	9.0	144
71	Influenza Vaccine Effectiveness in the 2011–2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clinical Infectious Diseases, 2014, 58, 319-327.	2.9	303
72	Influenza vaccine effectiveness in elderly people. Lancet Infectious Diseases, The, 2014, 14, 1169-1170.	4.6	1

#	Article	IF	CITATIONS
73	Evaluating Washington State's Immunization Information System as a Research Tool. Academic Pediatrics, 2014, 14, 71-76.	1.0	22
74	Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. Morbidity and Mortality Weekly Report, 2014, 63, 137-42.	9.0	53
75	Challenges in comparing the safety of different vaccination schedules. Vaccine, 2013, 31, 2126-2129.	1.7	6
76	The test-negative design for estimating influenza vaccine effectiveness. Vaccine, 2013, 31, 2165-2168.	1.7	406
77	Validation sampling can reduce bias in health care database studies: an illustration using influenza vaccination effectiveness. Journal of Clinical Epidemiology, 2013, 66, S110-S121.	2.4	11
78	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. American Journal of Epidemiology, 2013, 178, 1327-1336.	1.6	37
79	Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt. PLoS ONE, 2013, 8, e63605.	1.1	36
80	Haemophilus influenzae Type b Disease and Vaccine Booster Dose Deferral, United States, 1998-2009. Pediatrics, 2012, 130, 414-420.	1.0	12
81	Modeling Insights into <i>Haemophilus influenzae</i> Programs. Emerging Infectious Diseases, 2012, 18, 13-20.	2.0	14
82	Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors?. Pharmacoepidemiology and Drug Safety, 2011, 20, 858-865.	0.9	10
83	Risk Factors for Communityâ€Acquired Pneumonia in Immunocompetent Seniors. Journal of the American Geriatrics Society, 2009, 57, 882-888.	1.3	66
84	Confounding by Season in Ecologic Studies of Seasonal Exposures and Outcomes: Examples From Estimates of Mortality Due to Influenza. Annals of Epidemiology, 2009, 19, 681-691.	0.9	21
85	Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine, 2008, 26, 4947-4954.	1.7	144
86	Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet, The, 2008, 372, 398-405.	6.3	159
87	Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiology and Drug Safety, 2007, 16, 790-796.	0.9	21
88	Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology, 2006, 35, 337-344.	0.9	427
89	The Burden of Communityâ€Acquired Pneumonia in Seniors: Results of a Populationâ€Based Study. Clinical Infectious Diseases, 2004, 39, 1642-1650.	2.9	394